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Background: Biobank samples stored in biobanks give researchers and respiratory healthcare institutions access to
datasets of analytes valuable for both diagnostic and research practices. The usefulness of these samples in clinical
decision-making is highly dependent on their quality and integrity. New procedures that better preserve sample
integrity and reduce degradation are being developed to meet the needs of both present and future biobanking.
Hereby we present an automatic sample workflow scheme that is designed to handle high numbers of blood
samples.
Methods: Blood fractions are aliquoted, heat sealed using novel technology, and stored in 384 tube high-density
sample arrays.
Results: The newly developed 384 biobank rack system is especially suited for preserving identical small aliquots.
We provide data on robotic processing of clinical samples at −80°C, following initial processing, analysis and
shipping between laboratories throughout Europe. Subsequent to unpacking, re-sorting, and storage at these sites,
the samples have been returned for analysis. Biomarker analysis of 13 common tests in the clinical chemistry unit of
the hospital provides evidence of qualitative and stable logistics using the 384-sample tube system.
Conclusions: This technology development allows rapid access to a given sample in the frozen archive while
maintaining individual sample integrity with sample tube confinement and quality management.
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The future of biomedical sciences will be driven by the
ability to adopt novel technologies, generating large data
sets of data, to understand disease and to develop new
treatments. This is especially relevant to diseases such as
lung cancer (LC) and chronic obstructive pulmonary dis-
eases (COPD), responsible for high mortality and cost to
the European health care system. Cancer, and especially
lung cancer, as well as chronic obstructive pulmonary* Correspondence: gyorgy.marko-varga@elmat.lth.se
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in any medium, provided the original work is pdisease (COPD) are leading causes of smoking related
mortality worldwide. Overall, a therapeutic plateau has
been reached with conventional anti-cancer treatment
strategies such as cytotoxic agents, radiotherapy and sur-
gery. Given the still dismal survival rates, attention in re-
cent years has focused on novel molecular targeted
therapies with different mechanisms of action and better
toxicity profiles. Accordingly, there is a clinical need to:
(i) identify biomarkers that can help recognize patients
that respond to these therapies, (ii) detect tumor resist-
ance, (iii) and predict the efficacy of targeted drugs cost-
effectively. COPD is a progressive debilitating disease
that often is not diagnosed before extensive tissue de-
struction has occurred. Prevalence rates of COPD vary
across EU, ranging from 4 to 10% with an overall rate ofOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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rently COPD is under-diagnosed and is associated with
co-morbidity and risk for that increase the burden on
the healthcare system, hospitalization costs and mor-
tality. By implementing early detection, personalized
treatment and evaluation of response to treatment both
Lung Cancer and COPD have led to improved prognosis
and reduced cost to the healthcare system. These smoking
related respiratory diseases are multifactorial. Meaning
that not a single molecule is related to one disease or
clinical complaint, but rather to hundreds of molecules
that are interconnected or pathway related in addition
to protein complex formed. There is therefore a need
for selecting from multiple read-out signals. However,
this is hampered by the lack of tools and data for early
diagnosis. One new direction that is proving to be a
winning concept is the modeling of disease progression
and evaluation of treatment responses.
Biobanking is gaining momentum with an increasing
number of valuable patient samples linked with clinical
information that are being stored in biobanks around
the word [1,2]. The advancement in clinical research
where high quality samples are utilized in research has
increased significantly in the recent decade, but especially
in the last years [3-10]. The targeted treatments with
Personalized Medicines are becoming the new gener-
ation of drugs with high specificity and safety. In the
developments of these new drugs, high quality patient
samples are mandatory, where standardized Biobank
resources will play a major role [4,11]. It has resulted
in interest to share data, facilitated by biorepositories
of specimens that is linked to health care information,
where a lot of effort is given to meet the governance
challenges of Biobank archives now and in the future
[12]. Sample integrity is a real challenge, but also a
mandatory requirement for any patient read out. In
addition, life science clinical research material needs to
use standard procedures, optimized protocols and pro-
cessing cycle times, which are key aspects of work
flows to consider [13,14]. Protein and molecular deg-
radation is a well-known phenomenon that is directly
related to sample handling procedures, where sample
temperature, preparation times and sample preparation
procedures are some variables that will be directly related
to sample stability [15,16]. This is especially important
when samples are stored frozen in 5–12 ml tubes, thawed
and collected for analysis and then re-frozen again for fu-
ture use. When this procedure is repeated multiple times,
the composition of the original sample state is irreversibly
changed. This gives rise to changes in absolute amounts
of analytes that is not related to, e.g., the disease state of
the patient sample. Processing times of blood might vary
in-between some hours to 24 and 36 hours. The read-outs
from samples that have been exposed to these extendedprocessing times will vary. This is particularly critical
to RNA analysis, metabolomics quantitation as well as
protein expression analysis.
The processing protocols were worked out and
reported in large-scale studies, such as the UK Biobank
(http://www.ukbiobank.ac.uk/) and LifeGene (https://www.
lifegene.se/). Keeping an absolute control of patient sam-
pling, standardized procedures, validated sample handling
protocols and electronic surveillance of the sample life cycle
ranging from the needle in the arm of the patient to the
automated storage handling at −80°C will provide the
basis for high quality biobanks [2,14,17]. New technology
is changing a lot of the way that standard procedure in
hospitals is performed. Sample degradation and sample
losses due to evaporation along with cot effective sample
archiving are among the long-standing issues that are
most important in order to keep high quality of samples
for long periods.
By the implementation of e-health logistics, efficient
data storage and use, allows a data history to be established
where the patient treatments are linked to the decision
making of the physician, providing healthcare improve-
ments [18]. A novel technology that relate to biomarkers
and clinical status of the patients, is a great resource that
utilizes blood samples as a major biofluid resource. Blood
sample storages nowadays range from large national efforts
into smaller development labs where the biospecimen col-
lections are used as biobank assets, searching for healthcare
solutions [19,20].
The value that large scale biobanks provide paves the
way for new areas that opens up the opportunities such
as drug discovery, stem cell research and genetic re-
search [21-23]. This study presents novel developments
that improve the existing biobanking systems.
Methods
Materials and instruments
Matrix storage tubes and seals, 0.1 mL 384 2D tubes
(Thermo Scientific 384 well 2D coded storage tubes part
3815, MA, USA). In the sealing experiments we used a
WellMate dispenser (Thermo Scientific, MA, USA), a
small bore tubing cartridge (Thermo Scientific, MA, USA).
A 384 rack heat sealer (ALPS3000 Thermo Scientific,
MA, USA), the Heat 20 μm sealing foil (Easypierce,
Thermo Scientific, MA, USA), the PTFE Type K couples
TM Electronics (RS 409–4908, Thermo Scientific, MA,
USA), 8 channel USB data logger, and Picotech picolog
software (Pico technologies USBTC08). A Hamilton STAR
Liquid Handling Platform (Hamilton, Reno, NV) was
employed for automated aliquoting of blood samples.
CO-RE 480 standard volume tips (300 μL) with filters
and CO-RE 480 standard volume tips (1000 μL)
without filters were purchased from Hamilton
(Bonaduz, Switzerland). The variable temperature heat
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MA) was used for sealing 384-tubes with Easy Pierce
20 μm heat-sealing tape (AB-1720, Lot No: 115895)
(Thermo Fisher Scientific, MA). For registration of ali-
quots a VisionMate® scanner was used (Thermo Fisher
Scientific, MA). Nautilus LIMS (Thermo Fisher Scientific,
MA) was used throughout the entire study.
Blood samples
Blood samples were provided by healthy volunteers at
the Skåne University Hospital, Malmö, Sweden. Samples
were collected in the morning after breakfast intake. 10
mL blood was sampled repeatedly in primary tubes.
EDTA sample types were centrifuged for 10 minutes at
10,000 rpm, which is the standard procedure at the
hospital. 70-μL aliquots were dispensed into 384-rack
tubes (volume of 100 μL). These samples tubes were
stored at −80°C throughout the entire study, and on
dry ice upon transportation.
The collection of blood samples was approved by
the ethical board at Lund University (approval number:
LU 532–03).
Biomarker analysis
All analyses were performed by experienced clinical
chemistry staff at the Department of Clinical Chemistry,
Skåne University Hospital, Malmö, Sweden. The laboratory
is accredited by SWEDAC (Swedish Board for Accreditation
and Conformity Assessment). The following tests were run
using standard methods from Roche: α1-antitrypsin, ALAT
(alanine aminotransferase), albumin, apoA (apolipoprotein
A1), creatinine, CRP, cystatin C, estradiol, Fe, ferritin, bile
acid, glucose, fibrinogen, haptoglobin, HCG, IgA, IgG, IgM,
K, Mg, Na, EPK, LPK, TPK, TSH, total protein. All samples
were analyzed on a Cobas 8000 modular analyzer from
Roche (Basel, Switzerland).
Results and discussion
As the sample volume requirements are steadily decreas-
ing within the clinical chemistry departments in hospitals
around the world, blood sample handling from patients
becomes a critical part in the healthcare logistics. We
recently presented a 384 high density solution [17] that
is currently being implemented as an efficient and cheap
solution to Biobank archiving in clinical hospitals. The
384-rack is confined with a hard polymeric frame where
the tubes (384) are mounted. Manual or robotic picking
and sorting can be made for all of the tubes within the
384 biobank sample plate (10). The plates and foils have
been pre-tested for the used conditions to make sure
that there is no release of, e.g., plastifiers to contaminate
the samples.
Here we provide standardization and stability data
on the development of 384 Biobank sample systems,including an entire cycle of blood plasma samples that
were processed and sealed in the hospital in Malmö,
Sweden. The samples were stored at −80°C, transported
throughout Europe to Lichtenstein, processed by −80°C
robotics and shipped back to the hospital in Malmö, as
outlined in Figure 1.
Sample tube confinement and quality management
In order to be efficient and reliable, biobanks must adopt
and implement best practices with acceptable and standard-
ized sample tube processing for Biobank storage.
A 384 Sealer-Cutter (Thermo Fisher Scientific) was
evaluated, providing experimental evidence on sample
temperature maintenance throughout the 384-rack sealing
process utilizing sealing temperatures >150°C. One import-
ant question in these optimizations was: Are foil seal tubes
stable at low temperatures?
We ran the experiments at room temp, and storage after
liquid nitrogen storage over a period of 30 days, and with a
sample number of n = 30 or 16 for each measured points.
By positioning probes in the tubes, the probes were placed
in the tube just below the meniscus of the liquid. The
probes were inserted from the side to reduce the displace-
ment of sample in the well. The probe wire was routed out
of the rack down an adjacent tube. The base and one side
of the tube are removed to allow the wire to pass through.
The rest of the tube is kept where possible in tact to keep
the thermal mass of the test rack as close to a standard un-
modified rack as possible. Probe wires must be routed be-
tween tubes or around the skirt of the rack to allow the rack
to sit on the base of the tubes during the sealing process.
Holes in one end of the rack skirt allow the wires to exit the
side of the rack without interfering with the sealing process.
We performed a tube preparation i) by removing two
adjacent tubes from the rack; then ii) drilling a 1-mm
hole in one just above the ridge in the side. Next we re-
moved the side and base of the other tube to the same
height leaving the top of the tube intact. The probe wiring
will exit through the cut away tube as shown in upper and
lower images of Figure 2.
In order to investigate the temperature effect on the
liquid within the 384 tube sets, the datalogger was set to
log single measurements from the eight probes at 200
ms intervals and the log started prior to filling the racks.
Next, tube racks were filled with 70 μL of water. For the
wells containing temperature probes the liquid may
bridge across the well above the probe. It is necessary to
use a disposable tip to break the surface tension below
the probe so the liquid drops to the bottom of the tube.
The filled rack was then transferred to the ALPS 3000
and heat sealed, while sealing the door of the instrument
was held open to allow the wires to prevent the wires
getting trapped. Two test runs were made sealing at 165°C
for 1 second and then for 2 seconds. The same rack was
Figure 1 Schematic illustration of the blood sample stability procedure conducted in order to investigate biomarker stability.
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testing suggests sealing at 155°C for 0.5 seconds provides
adequate sealing without deforming the tubes unduly.
Sealing at 165 for 1 second melted more of the tube
than is desirable. Fine-tuning and adjustments can be
made at site and optimized accordingly.
The sample heating effects were investigated and
presented in Figure 3A and 3B with 1 and 2 seconds of
contact time at 165°C. The heat transfer effects will beFigure 2 Photos showing the tube preparation procedures for the tem
mounting of the temperature control of the 384-tube system (B).minimal with above conditions. Time will be sufficient
for the heat to diffuse from the foil to the sample. This
result in that the system is efficiently cooled before
much of the heat is transfers to the sample.
Figure 3 shows the temperature profiles upon sealing. It
can be seen from Figure 3B, that the temp rises to about
32°C, and by lowering the time to 1 second it reaches about
28°C. This small elevation of temperature will quickly
return to ambient temperature as shown in Figure 3.perature stability experiments (A) and photos showing the
Figure 3 Temperature dependence of automated sealing of the 384 sample tube systems at 165°C for (A) 1 and (B) 2s. The different
colors correspond to wells located in different regions of the rack.















165°C/1 second 3.79°C 59 s 4.53°C 45 s
165°C/2 second 6.47°C 52 s 8.39°C 34 s
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Table 1 and these results indicate that the recommended
sealing conditions for ALPS3000, 155°C for 0.5 seconds.
Long term blood sample stability
Long term stability of samples with respect to samples
volumes and evaporation in any storage temperature is
of major importance. Simply because a decreased volume
and alteration in sample volumes in Biobank tubes will
result in false diagnosis quantitations.
In order to investigate the tightness of our newly
developed sealing, and the automated processing of
384 systems, we compared the weight of empty tubes,
sealed empty tubes and tubes sealed with water inside.By comparing the data at ambient temperatures the
stability was investigated over a 30 day time period.
We found in the case of the sealed tubes both empty or
filled the results were found to be highly similar,
providing evidence that the evaporation from the 384
high-density biobank tube system insulates well after
Figure 4 Stability of filled (n = 30) and empty (n = 16) sealed sample tubes over 30 days.
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erated time frames in order to be able to extrapolate
long-term stability, we have utilized the medical packaging
accelerated ageing calculators (http://lso-inc.com/medical-
package-testing/accelerated-aging.html). By using this
calculation with the lower value (Q10), suggests that 1 day
at 20°C is approximately equivalent to 1 year at −80°C.
Robotic sample processing
The automated handling of samples in the biobank freezers
are in most cases separated from the actual archiving of the
sample racks. Robotic sorting and picking of sample tubes
from the sample rack by most instruments are performed
at −20°C. However, newly introduced robotic develop-
ments have proven to manage automated operations at
−80°C. This is of great value, since the both the storage
and the sample tube handling is performed at the same
temperature (−80°C), where the samples are more stable.
Another sample stability consideration is the general
principle that biobank samples are never re-used, i.e.,
that the samples from biobanks are never re-entered
back to −80°C storage. The reason for this strategy is
to maintain the sample quality over time, which is im-
possible if the sample goes through repetitive freeze-
thaw cycles. By utilizing high density 384-tube formats,
with 70 μL sample volumes, the single use approach
can be fulfilled [17]. In order to maintain the sample
integrity and quality over time, the principle of single
usage is also gaining acceptance.
Ultra low temperature robotic and 384-tube processing
The sample integrity in clinical samples has to be
maintained over longer time periods and provide a qualitythat can be used in global studies. The 384 high-density
tube format provides this opportunity, and in order to be
able to show the −80°C robotic processing procedures a
pilot experiment was conducted. Plasma samples (n = 768)
in Sweden with racks of 384 tubes with a sample volume
of 70 μL were shipped to Lichtenstein on dry ice. 13
biomarkers were quantified within the plasma samples
in Sweden as a baseline. The same samples shipped to
Lichtenstein, processed by the −80°C robotic picker
and sorter (Kiwi, Liconic, Lichtenstein) in 10 cycles
with a random sorting procedure. The robotic picker
was operating constantly sorting the tubes in a random
walk procedure within the 384-rack, from one position
to the next. At no instance did the robotic arm drop or
misplace the plasma sample tubes.
Next, the 384 plasma tube samples (n = 45) were
shipped back to the University hospital in Malmö on
dry ice and analyzed using the 13 biomarker assays.
These assays were chosen by the standards of highest
frequency tests in the hospitals in southern Sweden
where the patients with various diseases are screened.
As shown in Figure 5, the difference in-between the
two analysis are negligible, which points to the fact
that the −80°C robotic processing does not influence
the stability of blood plasma samples.
Conclusions
The current manuscript is of major relevance to the
diagnostic respiratory field as it outlines the standardization
and qualitative aspects of blood sample processing in
large-scale biobanking.
Biobanks are dependent upon effective sample pro-
cessing and stable long-term low temperature storage
Figure 5 Histograms of 13 biomarkers processed over a 7-week period using the 384-samples tube system.
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stable storage are currently being developed. Auto-
matic robotic systems will be an essential component
for the success of standardization procedures that
speak to the preservation of sample integrity. This will
be especially needed in studies of large number patient
cohorts where samples are collected and processed in
multitudes of laboratories at national and global levels
of study. High cost that is associated with investments
in robotic instrumentation is a challenge in a high
quality driven healthcare society. Large scale processing
on the other hand puts extremely high demands on
manual sample handling and is close to impossible. As
ultra-low temperatures demands for increased power
consumptions, the lower temperatures also brings an-
other challenge along that might be a disadvantage and
that is huge temperature alterations upon power cuts orother electronic problems that ultimately will change
the temperature of the sample.
In addition to their usefulness in clinical decision
making, stable biobanked samples are also of import-
ance to drug development, biomarker identification,
sentinel studies of health and disease in society in both
academic and regulatory settings [24].
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